Humacyte (NASDAQ:HUMA) Posts Earnings Results, Beats Estimates By $0.01 EPS

Humacyte (NASDAQ:HUMA) announced its quarterly earnings data on Wednesday. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01, Zacks reports. Humacyte had a negative net margin of 1,998.87% and a negative return on equity of 990.48%.

Here are the key takeaways from Humacyte’s conference call:

• Symvess sales increased to $0.5 million in Q1 2026 from $0.1 million a year ago, but management said adoption is still too slow and that stronger commercial execution is needed.
• The company reshaped its commercial organization with new senior hires, including a Chief Commercial Officer and Chief Surgical Officer, to improve surgeon education, hospital penetration, and IDN coverage.
• Humacyte said its dialysis access Phase III trial is on track for top-line interim results around June 11, with 120 patients enrolled and a supplemental BLA planned for the second half of 2026 if results are positive.
• The company restructured its workforce in May, cutting 45 employees, and expects about $0.8 million in severance charges despite projecting roughly $14.3 million in savings for the rest of 2026.
• Humacyte ended Q1 with $48.9 million in cash and restricted cash; however, it reported a $17.6 million net loss, driven largely by lower non-cash income from contingent earn-out remeasurement.

Humacyte Trading Up 26.3%

HUMA traded up $0.24 during mid-day trading on Wednesday, hitting $1.15. The stock had a trading volume of 23,195,831 shares, compared to its average volume of 6,454,625. The stock’s fifty day simple moving average is $0.86 and its 200-day simple moving average is $1.07. The company has a debt-to-equity ratio of 20.08, a current ratio of 3.69 and a quick ratio of 2.95. The firm has a market capitalization of $255.10 million, a price-to-earnings ratio of -5.69 and a beta of 2.31. Humacyte has a 1-year low of $0.55 and a 1-year high of $2.93.

Institutional Investors Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Prudential Financial Inc. acquired a new stake in shares of Humacyte during the 2nd quarter worth about $28,000. Price T Rowe Associates Inc. MD increased its stake in shares of Humacyte by 21.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 76,017 shares of the company’s stock valued at $73,000 after purchasing an additional 13,175 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Humacyte by 41.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 45,960 shares of the company’s stock worth $96,000 after purchasing an additional 13,407 shares in the last quarter. Financial Advisors Network Inc. acquired a new position in Humacyte during the 2nd quarter worth approximately $28,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Humacyte by 25.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,975 shares of the company’s stock valued at $161,000 after acquiring an additional 15,649 shares during the period. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HUMA has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a research note on Friday, April 10th. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research note on Tuesday, April 28th. BTIG Research decreased their price objective on shares of Humacyte from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Wednesday. Benchmark decreased their price objective on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 21st. Finally, Wall Street Zen cut shares of Humacyte from a “sell” rating to a “strong sell” rating in a research note on Saturday, April 11th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.57.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.